Table 2.

OS Results to Date

Result	First Interim OS Analysis*		Second Interim OS Analysis†
	GC + PL (n = 242)	GC + BV (n = 242)	GC + PL (n = 242)	GC + BV (n = 242)
Median OS, months	29.9	35.5	35.2	33.3
95% CI	26.4 to NE	30.0 to NE	29.9 to 40.3	29.8 to 35.5
HR	0.751		1.027
95% CI	0.537 to 1.052		0.792 to 1.331

Abbreviations: BV, bevacizumab; GC, gemcitabine plus carboplatin; NE, not estimable; OS, overall survival; PL, placebo.

^*Data cutoff date: September 17, 2010.

^†Data cutoff date: August 29, 2011.